Advanced search
Publication Cover
Leukemia & Lymphoma Volume 45, 2004 - Issue 11
Submit an article Journal homepage
62
Views
30
CrossRef citations to date
0
Altmetric
Research Article

Severe Hepatitis and Complete Molecular Response Caused by Imatinib Mesylate: Possible Association of Its Serum Concentration with Clinical Outcomes

Satoru Kikuchi Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
,
Kazuo Muroi Division of Cell Transplantation and Transfusion Jichi Medical School Minamikawachi Japan
,
Satoko Takahashi Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
,
Chizuru Kawano-Yamamoto Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
,
Masaaki Takatoku Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
,
Akira Miyazato Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
,
Tadashi Nagai Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
,
Masaki Mori Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
,
Norio Komatsu Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
&
Keiya Ozawa Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
 show all
Pages 2349-2351 | Published online: 01 Jul 2009

References

  • Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., et al. (2001) "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia", The New England Journal of Medicine, 344, 1031 — 1037.
  • Sawyers, C.L., Hochhaus, A., Feldman, E., Goldman, J.M., Miller, C.B., Ottmann, O.G., et al. (2002) "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study", Blood, 99, 3530–3539.
  • Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., et al. —International STI571 CML Study Group. (2002) "Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia", The New England Journal of Medicine, 346, 645 —652.
  • Kantarjian, H.M., Cortes, J., O'Brien, S., Giles, F.J., Albitar, M., Rios, M.B., et al. (2002) "Imatinib mesylate (5TI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase", Blood, 99, 3547–3553.
  • Hensley, M.L. and Ford, J.M. (2003) "Imatinib treatment: Specific issues related to safety, fertility, and pregnancy", Seminars in Hematology, 40\(Suppl 3), 21— 25.
  • Ohyashiki, K., Kuriyama, Y., Nakajima, A., Tauchi, T., Ito, Y., Miyazawa, H., et al. (2002) "Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis", Leukemia, 16, 2160 — 2161.
  • James, C., Trouette, H., Marit, G., Cony-Makhoul, P. and Mahon, F.X. (2003) "Histological features of acute hepatitis after imatinib mesylate treatment", Leukemia, 7, 978–979.
  • Parise, R.A., Ramanathan, R.K., Hayes, M.J. and Egorin, M.J. (2003) "Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma", Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 791, 39–44.
  • O'Brien, S.G., Peng, B., Dutreix, C., Mehring, G., Milosavljev, S., Gapdeville, R., et al. (2001) "A pharmacokinetic interaction of glivec and simvastatin, a cytochrome 3A4 substrate, in patients with chronic myeloid leukemia", Blood, 98, 141a (Abstract).
  • Goodman, Z.D. (2002) "Drug hepatotoxicity", Clinics in Liver Disease, 6, 381–397.
  • Gambacorti-Passerini, C., Zucchetti, M., Russo, D., Frapolli, R., Verga, M., Bungaro, S., et al. (2003) "Alpha! acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacoki-netics in chronic myeloid leukemia patients", Clinical Cancer Research, 9, 625–632.
  • www.eudra.org/humandocs/PDFs/EPAR/glivec/241801en6.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.